GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2005-04-26
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00109226
A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2005-04-26
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00109239
A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g
Phase 3
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2005-04-26
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00109252
A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-04-26
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00109200
An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143g
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-04-26
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00109187
A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy
Phase 2
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2005-04-26
- Last Posted Date
- 2015-07-02
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00109265
A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal Cancer
Phase 3
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00109070
An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study
Phase 2
Completed
- Conditions
- Cancer
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00109057
A Study of Patients With HER2-Positive Metastatic Breast Cancer
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2005-03-15
- Last Posted Date
- 2010-05-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT00105456
National Cooperative Growth Study (NCGS): A Post-marketing Surveillance Program for Nutropin, Nutropin AQ, Nutropin Depot, and Protropin
Completed
- Conditions
- Growth Disorders
- Interventions
- Biological: SomatremBiological: Somatropin
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 65205
- Registration Number
- NCT00097539
© Copyright 2025. All Rights Reserved by MedPath